VISCHER acted as legal counsel to BID Equity on this transaction. BID Equity acquires Realview AG, which develops and distributes software for the Swiss construction industry....
BID Equity’s Acquisition Of Realview AG
Memo Therapeutics AG’s CHF20 Million Additional Series C Financing Round
VISCHER advised Ysios Capital and Kurma Partners. Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised...
EnBW’s Partnership With Narrowin GmbH
VISCHER advised narrowin GmbH on all aspects on this transaction. The German energy supplier EnBW enters into a partnership with narrowin GmbH, a Swiss cybersecurity start-up....
Odne’s $5.5 Million Financing Round
VISCHER AG acted for Odne on the deal. Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch for...
Artiria Medical SA’s CHF6 Million Series A2 Financing Round
VISCHER acted for Artiria Medical SA on the deal. Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation neuro-interventional products for stroke and aneurysms, closed...
Deutsche Invest’s Acquisition of Iconia Group From AFINUM
VISCHER advised AFINUM on all legal aspects of the transaction. AFINUM and the management have sold Iconia Group to Deutsche Invest. Iconia Group is a global...
EraCal Therapeutics AG’s €235 Million Licensing Agreement To Novo Nordisk
VISCHER advised EraCal on all legal issues related to the transaction. EraCal Therapeutics has signed a collaboration and license agreement with Danish pharma producer Novo Nordisk....
GlycoEra’s Incresing Its Series A Financing Round
Vischer advised GlycoEra AG on the deal. GlycoEra AG has closed CHF 45m (USD 49m) Series A financing round, co-led by re-nowned US and European life...
DomoHealth SA’s CHF8.5 Million Series C Financing Round
VISCHER advised DomoHealth SA on the financing round. DomoHealth SA, a leading company in the digital health segment developing innovative solutions in the field of patient...
Danstar Ferment AG (Lallemand Inc.)’s Take-Over of Evolva AG
VISCHER advised Danstar Ferment AG on the Swiss legal aspects of this transaction. Danstar Ferment AG, a Swiss subsidiary of Canadian multi-national, Lallemand Inc., has successfully...
Proteomedix and Blue Water Biotech’s Forms Onconetix
VISCHER advised Proteomedix on the deal. Proteomedix AG, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech, Inc. (Nasdaq: BWV) are forming together a company...
Constructor Group’s Corporate Reorganization in Switzerland
VISCHER advised Constructor Group on the operation. Through its for-profit and nonprofit entities that combine notably a university, a research center, businesses, consulting services, incubation, and...